FindTrial
Sign In

Investigation of prevalence of anti-PF4 antibodies recognizing the binding site of VITT antibodies on PF4 and of anti-PF4/heparin antibodies recognizing the binding site of HIT antibodies in normal individuals and patients referred with the clinical suspicion of either HIT, or VITT, and in patients with thrombosis of unknown cause

Investigation of prevalence of anti-PF4 antibodies recognizing the binding site of VITT antibodies on PF4 and of anti-PF4/heparin antibodies recognizing the binding site of HIT antibodies in normal individuals and patients referred with the clinical suspicion of either HIT, or VITT, and in patients with thrombosis of unknown cause

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00032653
Enrollment
500
Registered
2023-09-11
Start date
2023-08-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-PF4-antibody-associated disorders

Interventions

Group 1: Patients referred to the Platelet Laboratory of the Universitätsmedizin Greifswald with the clinical suspicion of HIT. Group 2: Patients referred to the Platelet Laboratory of the Universitä

Sponsors

Universitätsmedizin Greifswald
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patient samples with an optical density (OD) > 1 in anti PF4/heparin IgG ELISA (standard screening assay of the laboratory)

Exclusion criteria

Exclusion criteria: No anti-PF4 antibodies detectable

Design outcomes

Primary

MeasureTime frame
Presence of anti-PF4/heparin antibodies or anti-PF4 antibodies—

Secondary

MeasureTime frame
Thrombembolic Events Thrombocytopenia—

Countries

Germany

Contacts

Public ContactLinda Schönborn

Universitätsmedizin Greifswald

linda.schoenborn@med.uni-greifswald.de+49 3834865479

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026